Nuclear Medicine
PSMA (R+D)
Name:
18F -PSMA-1007 (R&D)
Active Principle:
(3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)methyl)phenyl)- 3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid
Therapeutic Action:
It is indicated for the detection and evaluation of prostate cancer from the initial diagnosis to the monitoring of castration-resistant metastases.
Nuclear Medicine
PSMA (R+D)
Name:
18F -PSMA-1007 (R&D)
Active Principle:
(3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)methyl)phenyl)- 3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid
Therapeutic Action:
It is indicated for the detection and evaluation of prostate cancer from the initial diagnosis to the monitoring of castration-resistant metastases.
